1-(6-(4-((4-chloro-3-(trifluoromethyl)phenyl)aminocarbonylamino)phenoxy)benzthiazol-2-yl)-3-(butyl)urea | 433225-39-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(6-(4-((4-chloro-3-(trifluoromethyl)phenyl)aminocarbonylamino)phenoxy)benzthiazol-2-yl)-3-(butyl)urea
• 英文别名: 1-Butyl-3-[6-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-1,3-benzothiazol-2-yl]urea
• CAS: 433225-39-9
• 化学式: C₂₆H₂₃ClF₃N₅O₃S
• 分子量: 578.015
• InChiKey: NPMUXZRZNWVKMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  39
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  133
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Chemical compounds
  申请人：——

  公开号：US20040082583A1

  公开（公告）日：2004-04-29

  Benzimidazole derivatives, which are useful as TIE-2 and/or VEGFR2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

  本文描述了作为TIE-2和/或VEGFR2抑制剂有用的苯并咪唑衍生物。所述发明还包括制备这种苯并咪唑衍生物的方法，以及在治疗过度增殖性疾病中使用它们的方法。
• CHEMICAL COMPOUNDS
  申请人：Cheung Mui

  公开号：US20070249600A1

  公开（公告）日：2007-10-25

  Benzimidazole derivatives, which are useful as TIE-2 and/or VEGFR2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

  本文描述了作为TIE-2和/或VEGFR2抑制剂有用的苯并咪唑衍生物。所述发明还包括制备这种苯并咪唑衍生物的方法，以及在治疗过度增生性疾病中使用它们的方法。
• BENZIMIDAZOLE DERIVATIVES USEFUL AS TIE-2 AND/OR VEGFR-2 INHIBITORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1341771A2

  公开（公告）日：2003-09-10
• US7238813B2
  申请人：——

  公开号：US7238813B2

  公开（公告）日：2007-07-03
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2002044156A2

  公开（公告）日：2002-06-06

  Benzimidazole derivatives of Formula (I), which are useful as TIE-2 and/or VEGFR2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.